Spinal cord injury (SCI) represents one of the most devastating neurological conditions, profoundly disrupting sensory, motor, and autonomic functions below the level of injury. Its consequences extend far beyond mere physical impairment, encompassing a complex web of psychological and social challenges that pose a substantial burden on patients and their caregivers. Among the myriad complications that arise following SCI, the loss of voluntary control over bladder function remains particularly debilitating, undermining patient autonomy, quality of life, and dignity. The intricate interplay of neural pathways governing lower urinary tract function becomes severely compromised, leading to neurogenic bladder dysfunction that is intricately linked with heightened risks of urinary tract infections, renal damage, and incontinence.

For decades, researchers have relied extensively on animal models to unravel the pathophysiological underpinnings of SCI and its associated comorbidities. These preclinical platforms have proven indispensable in dissecting the cellular and molecular cascades triggered by spinal trauma, enabling the identification of potential therapeutic targets. Through controlled experimental conditions, scientists have been able to mimic various types of SCI lesions, from contusions to complete transections, affording nuanced insights into injury severity and plasticity mechanisms. Moreover, animal models facilitate the rigorous testing of novel interventions — ranging from pharmacological agents to neuromodulatory devices — that aim to restore neural circuits or promote regeneration within the damaged spinal cord.

Despite these advancements and the critical role that animal experimentation has played, a persistent and contentious debate surrounds the translational effectiveness of these models. The stark reality is that many promising therapeutic strategies that yielded encouraging results in animals have failed to replicate similar benefits in human clinical trials. This translational gap underscores the biological and physiological differences between species, as well as the complexity of accurately reproducing the heterogeneity and chronicity of human SCI in simpler model organisms. Ethical considerations also compound the urgency for innovation, fueling a global momentum toward reducing reliance on animal studies where feasible and developing alternative methodological approaches.

In the evolving landscape of biomedical research, technological progress is fostering the emergence of cutting-edge in vitro and in silico models that promise to complement or potentially supplant traditional animal-based experiments. Organoids, microfluidic systems, and advanced computational simulations are gaining traction as sophisticated tools capable of recapitulating key elements of spinal cord architecture and function. These platforms aspire not only to reduce animal use but also to offer greater experimental control and reproducibility, potentially accelerating the pipeline from bench to bedside. Importantly, regulatory agencies are increasingly acknowledging and supporting these innovative approaches, embedding them within frameworks that ensure safety and efficacy without compromising ethical standards.

A nuanced understanding of neuro-urological dysfunction post-SCI exemplifies the complexity of this translational challenge. The control of bladder function is regulated by an intricate network involving supraspinal centers, spinal interneurons, and peripheral autonomic pathways. Following SCI, this orchestration is disrupted, with varying patterns of dysfunction depending on the lesion level and severity. Animal models, ranging from rodents to large mammals, capture distinct aspects of these patterns and have been pivotal in characterizing mechanisms like detrusor overactivity, sphincter dyssynergia, and altered afferent signaling. However, clinical phenotypes observed in humans often present additional layers of intricacy that are not fully paralleled in animal studies, highlighting the necessity for enhanced model fidelity.

Within experimental contexts, the choice of animal species and injury paradigms is driven by the specific research question being addressed. Rodents, primarily rats and mice, are favored for their genetic tractability, well-established behavioral assays, and cost-effectiveness. Larger mammalian models such as cats, dogs, and non-human primates offer advantages in anatomical and physiological similarity to humans but involve substantial ethical and logistical challenges. Each model carries inherent limitations in terms of reproducing chronic injury states, co-morbid conditions, and the psychosocial dimensions of SCI, factors that have contributed to translational discrepancies in therapeutic development.

Advances in imaging technologies, electrophysiological monitoring, and biomarker identification have supplemented animal research by enabling more precise phenotyping of SCI and its neuro-urological consequences. Functional MRI, calcium imaging, and optogenetics provide unprecedented views into spinal cord circuitry and its plastic adaptations, facilitating the assessment of intervention efficacy at multiple neurobiological scales. Nonetheless, integrating these sophisticated methods across species and in translational studies demands rigorous standardization and validation to ensure data comparability and clinical relevance.

Contemporary therapeutic strategies emerging from animal research encompass pharmacological modulators targeting neurotransmitter systems, stem cell transplantation to replace lost or damaged neurons, and bioengineering approaches aimed at bridging lesion gaps or providing scaffolding for axonal regrowth. Neuromodulation techniques such as electrical stimulation of sacral nerves or the spinal cord itself have shown promise in restoring partial bladder control, with a handful of such technologies transitioning into clinical trials. These advances underscore the indispensable role of preclinical models in pioneering interventions that address both the neurogenic bladder and the broader spectrum of SCI-induced disability.

Looking ahead, the field stands at a crossroads, poised between longstanding reliance on animal experimentation and the transformative potential of emerging modeling strategies. While animal models remain critical for certain studies, the integration of alternative approaches is anticipated to accelerate in the coming decade. Such a paradigm shift will depend not only on technological innovations but also on a collaborative ecosystem involving scientists, clinicians, regulatory bodies, and patient advocacy groups to harmonize research priorities and ethical considerations.

Indeed, the question of whether animal models will retain their central role in neuro-urological SCI research by 2035 reflects broader themes in biomedical research ethics, experimental rigor, and translational success. A hybridized methodology that combines animal models with advanced in vitro systems and computational models may offer the most fruitful path forward, marrying the biological relevance of whole organisms with the precision and scalability of engineered platforms. This integrative approach could foster more effective therapies for SCI patients suffering from bladder dysfunction, reducing the human and economic toll of this challenging condition.

Crucially, patient-centered outcomes must guide research priorities, ensuring that innovations translate into tangible improvements in bladder control, autonomy, and quality of life. The intersection of neurobiology and urology demands interdisciplinary collaboration and sustained investment in technologies that can simulate the complex neurogenic bladder environment. Such efforts will define the scientific landscape of SCI research, promising new horizons in repair and rehabilitation.

Regulatory frameworks will also play a pivotal role in steering the future of SCI research methodologies. Agencies are increasingly promoting the 3Rs principle—replacement, reduction, and refinement of animal use—with heightened scrutiny on the predictive validity of animal models. Enhanced guidelines supporting alternative models could incentivize their adoption and facilitate expedited regulatory approval for novel therapeutics. This dynamic will likely reshape both academic and industry research strategies in neuro-urology.

In sum, while animal models have undeniably been cornerstones of SCI neuro-urological research, the field is undergoing a fundamental transformation informed by ethical imperatives, scientific rigour, and technological innovation. The trajectory toward 2035 suggests a diminishing but not extinguished role for animal experimentation, coexisting with advances that enhance the resolution and relevance of preclinical research. This evolution holds promise to one day liberate SCI patients from the grip of neurogenic bladder dysfunction, restoring dignity and function through precision medicine grounded in robust scientific inquiry.

The road ahead is both challenging and exhilarating, promising breakthroughs borne from an unprecedented synergy of traditional biological models and revolutionary engineering and computational tools. As neuroscience and urology converge on the frontier of spinal cord repair, the legacy of animal research endures—not as a relic but as a foundational pillar supporting the ascent toward a future where SCI is a treatable rather than a life-altering diagnosis.

Subject of Research: Animal models of spinal cord injury in neuro-urological research

Article Title: Animal models of spinal cord injury in neuro-urological research

Article References:
Giannotti, A., Aguinaga, D.M., Ferreira, A. et al. Animal models of spinal cord injury in neuro-urological research. Nat Rev Urol (2026). https://doi.org/10.1038/s41585-026-01163-6

Image Credits: AI Generated

Atherosclerosis remains the foremost cause of cardiovascular disease-related morbidity and mortality globally, posing a substantial challenge to healthcare systems. Although traditional risk factors such as diet, lifestyle, and genetics have been extensively studied, recent advances have illuminated the pivotal role played by epigenetic mechanisms in shaping the onset and progression of atherosclerotic disease. Epigenetics, the reversible modulation of gene expression without alterations to the DNA sequence, encompasses DNA methylation, histone modifications, and non-coding RNAs, all of which intricately orchestrate cellular behavior within vascular tissues.

Emerging research reveals that DNA methylation patterns, both globally across the genome and in gene-specific loci, critically regulate cellular proliferation and inflammatory responses integral to atherogenesis. Hypomethylation or hypermethylation at particular sites can drastically affect the transcriptional activity of genes responsible for maintaining vascular homeostasis. This phenomenon underscores a dynamic regulatory system where environmental cues and pathological stimuli can induce lasting epigenomic changes that propagate vascular dysfunction and inflammation.

Histone post-translational modifications add another sophisticated layer to this epigenetic landscape. Primarily involving acetylation and methylation of histone proteins, these modifications influence chromatin structure and, consequently, gene accessibility. Within atherosclerotic plaques, histone modifications have been shown to govern networks of genes related to lipid metabolism, cellular plasticity, and inflammatory signaling. Such modifications enable vascular cells to adapt to inflammatory and metabolic stress by modulating transcriptional programs essential for plaque development and instability.

Non-coding RNAs have further expanded the complexity of epigenetic regulation within the vascular milieu. Long non-coding RNAs (lncRNAs) shape the transcriptomic profiles of specific cell types and exert control over the localization and activity of epigenetic enzymes. This targeting ensures that epigenetic remodeling is not only precise but also tailored to cellular needs in the context of vascular remodeling. Concurrently, microRNAs (miRNAs), small regulatory RNAs, predominantly mediate post-transcriptional gene silencing but have been identified to participate in non-canonical functions that influence vascular cell phenotype and immune responses.

The integration of multi-omics approaches, combining epigenomics, transcriptomics, and proteomics, has revolutionized our understanding of the cell-specific epigenetic contributions in atherosclerosis. These technological advancements enable the dissection of complex intercellular interactions within plaques and facilitate the mapping of genetically associated loci to discrete epigenetic modifications. This multidimensional insight is vital to unraveling the heterogeneity of atherosclerotic lesions and their diverse clinical manifestations.

In vascular endothelial cells, epigenetic alterations modulate barrier function, inflammation, and response to shear stress, all of which are critical in the initial stages of atherogenesis. Endothelial dysfunction triggered by epigenetic dysregulation sets the stage for immune cell recruitment and plaque formation. Meanwhile, vascular smooth muscle cells (VSMCs) exhibit remarkable plasticity through epigenetic reprogramming that drives their phenotypic switch from a contractile to a synthetic state, facilitating extracellular matrix remodeling and plaque stability or vulnerability.

Immune cells within the atherosclerotic microenvironment are also subject to profound epigenetic modulation. Macrophages, T cells, and other leukocytes display distinct epigenetic signatures that influence their activation states and inflammatory profiles. Epigenetic memory within these immune populations can perpetuate chronic vascular inflammation, underscoring the need for targeted interventions that modulate immune cell epigenomes to mitigate atherosclerotic progression.

Preclinical studies have leveraged these mechanistic insights to explore epigenetic drug candidates capable of attenuating plaque burden and vascular inflammation. Histone deacetylase inhibitors, DNA methylation modulators, and RNA-based therapeutics have demonstrated efficacy in experimental models, highlighting their potential to recalibrate aberrant gene expression patterns driving disease. However, challenges remain in achieving cell-type specificity, minimizing off-target effects, and ensuring the durability and safety of such interventions in humans.

A critical hurdle for translational success lies in the delivery mechanisms for epigenetic therapies. Nanoparticle-based systems and ligand-targeted delivery platforms are under investigation to enhance precision targeting of vascular and immune cells within plaques. These delivery technologies aim to maximize therapeutic benefit while circumventing systemic toxicity, thereby advancing the clinical applicability of epigenetic modulators.

Long-term safety is another paramount consideration as epigenetic drugs inherently affect gene regulation, potentially leading to unforeseen consequences. Rigorous preclinical evaluation and carefully designed clinical trials are imperative to balance efficacy with safety, ensuring that epigenetic therapies can be integrated into cardiovascular medicine without triggering deleterious off-target effects.

The prospect of leveraging epigenetic regulation heralds a transformative shift in cardiovascular therapeutics, enabling precision medicine tailored to an individual’s unique epigenomic landscape. By elucidating the dynamic and reversible nature of epigenetic modifications in vascular cells and immune populations, researchers are charting new pathways to mitigate atherosclerosis beyond conventional lipid-lowering and anti-inflammatory strategies.

Continued exploration into the interplay between genetic predisposition and environmental influences mediated by epigenetic mechanisms promises to deepen our understanding of atherosclerosis pathobiology. This holistic view integrates molecular, cellular, and systemic insights, empowering the development of sophisticated therapeutics capable of interrupting the disease process at its regulatory roots.

In summary, the frontier of atherosclerosis research lies at the intersection of epigenetics and vascular biology. The potential to manipulate gene expression programs with high specificity and reversibility offers an unprecedented opportunity to combat the global burden of cardiovascular disease. As the field advances, collaboration across disciplines and innovative technological approaches will be essential to realize the therapeutic promise of epigenetic modulation in clinical practice.

With ongoing efforts focused on unraveling cell-specific epigenetic mechanisms, refining drug delivery technologies, and ensuring long-term treatment safety, the era of epigenetics-driven precision cardiology is on the horizon. This paradigm shift not only holds the key to diminishing the impact of atherosclerosis but also exemplifies the broader potential of epigenetic therapies across complex diseases.

Subject of Research: Epigenetic regulation mechanisms in atherosclerosis and their potential for therapeutic intervention.

Article Title: Epigenetic regulation in atherosclerosis and its therapeutic potential

Article References:
Santovito, D., Atzler, D. & Weber, C. Epigenetic regulation in atherosclerosis and its therapeutic potential. Nat Rev Cardiol (2026). https://doi.org/10.1038/s41569-026-01313-8

Image Credits: AI Generated

Girls as young as 11 will be eligible for puberty blockers under the restarted Pathways trial after the MHRA agreed new protocols despite an outcry and indications it could have been limited to 14-plus.

The post Girls Aged 11 Eligible for Restarted Puberty Blocker Trial appeared first on The Daily Sceptic.

In the complex landscape of cellular biology, lipid transport stands as a fundamental process indispensable to life. All cells are enveloped by a thin, flexible membrane primarily composed of lipids, which not only serve as barriers but also actively participate in critical cellular functions. The transport of these lipids across membranes is orchestrated by specialized proteins, the lipid transporters, which facilitate the movement of lipid molecules from one side of the membrane bilayer to the other. This transport underpins a myriad of physiological activities, including the assembly and preservation of cellular membranes, lipid provision to mitochondria, and signaling pathways involved in programmed cell death. Despite its significance, the individual dynamics of lipid transport proteins have remained elusive due to limitations in traditional investigative methodologies.

Historically, investigations into lipid transporter proteins have utilized ensemble measurement techniques. These conventional methods analyze millions of protein molecules simultaneously, yielding averaged data that mask the heterogeneity among individual transporters. Consequently, the unique behaviors, efficiency rates, and mechanistic variations of single lipid transport proteins could not be discerned. Understanding these subtle distinctions is pivotal for unearthing nuanced cellular processes and developing targeted therapeutic interventions. Addressing this gap, an international cohort of researchers has pioneered a breakthrough technique leveraging highly sensitive imaging methodologies combined with high-throughput capabilities to observe and quantify the lipid transport activity of individual proteins in real-time.

Central to the research is the protein VDAC1 (Voltage-Dependent Anion Channel 1), which plays a crucial role in the delivery of lipids to mitochondria, thereby sustaining mitochondrial membrane integrity and function. Notably, VDAC1’s lipid transport activity is contingent upon its assembly into dimers—complexes formed by the pairing of two protein molecules. The novel imaging approach revealed a striking variability in the lipid transport efficiency among these dimers. Whereas some VDAC1 dimers were capable of translocating thousands of lipid molecules per second, others exhibited markedly reduced activity, and a subset appeared completely inactive. This individual-level heterogeneity, unnoticed in previous bulk assays, can be attributed to the specific spatial conformations that these dimers adopt, influencing their functional interfaces for lipid translocation.

This heterogeneity extends beyond mere functional curiosity; it introduces a paradigm shift in understanding membrane protein behavior, suggesting that protein complex formation—its precise structural arrangement—critically governs functional outcomes. Molecular dynamic simulations provided corroborative evidence, demonstrating that only particular dimer configurations furnish the optimal surface topology necessary for efficient lipid movement. These insights prompt a reevaluation of lipid transporter function that moves beyond static representations, embracing the dynamic and variable nature of protein assemblies in vivo.

The methodology that underpins these discoveries is itself a technical marvel. By employing a single vesicle fluorescence microscopy platform, the researchers can isolate individual liposomes encapsulating single protein entities. Fluorescent probes sensitive to lipid translocation allow precise quantification of scrambling events—a process by which phospholipids redistribute between the bilayer leaflets—on a vesicle-by-vesicle basis. This level of granularity affords unprecedented resolution in kinetic measurements, avoiding the artifacts inherent in bulk assays where asynchronous activity and averaged signals convolute interpretation.

Moreover, this platform’s versatility is notable. It is not confined to the study of VDAC1 but adaptable to a broad spectrum of lipid transporters implicated across diverse cellular pathways. By systematically altering membrane lipid compositions or introducing cofactors such as metal ions, researchers can dissect how microenvironmental factors influence transporter kinetics. This feature facilitates comprehensive structure-function analyses, enabling the delineation of regulatory mechanisms and potential modulatory elements affecting transport efficacy.

From a translational perspective, the implications of these findings are profound. Mitochondrial dysfunction underlies a constellation of pathologies ranging from metabolic disorders to neurodegenerative diseases and certain hematological conditions. Aberrant lipid transport may contribute to these dysfunctions by compromising membrane integrity or signaling fidelity. Enhanced comprehension of individual transporter behavior could usher in new diagnostic markers or therapeutic targets. For instance, modulating the assembly state or stabilizing the active dimer conformation of VDAC1 may represent novel strategies to restore or optimize mitochondrial lipid homeostasis.

Furthermore, the study’s insights into the variability of lipid transporters invite reconsideration of drug design paradigms. Rather than targeting proteins en masse, future pharmacological interventions might be tailored to influence specific functional states or conformers of lipid transport proteins, enhancing efficacy and minimizing off-target effects. Such precision medicine approaches would benefit immensely from platforms capable of high-resolution characterization as demonstrated here.

The scientific community also gains a powerful tool to unravel the complexities of lipid dynamics and membrane biology. By circumventing the averaging problem intrinsic to ensemble experiments, researchers can now observe phenomena such as transient conformational states, stochastic transport events, and cooperative interactions among protein assemblies. This deeper understanding is essential for decoding the lipid-mediated regulatory codes that orchestrate cellular responses to environmental cues and stressors.

Importantly, this research exemplifies the synergy between experimental innovation and computational modeling. The integration of single-molecule fluorescence microscopy with molecular simulations not only confirms empirical observations but also guides hypothesis generation and experimental design. Such interdisciplinary approaches are increasingly vital for tackling intricate biological questions that span scales from atomic-level interactions to cellular physiology.

Looking ahead, the deployment of this single-vesicle fluorescence microscopy platform promises to accelerate discoveries in membrane biology and lipid transport. As the method is refined and applied to other protein families, it may reveal fundamental principles governing membrane asymmetry, lipid signaling, and protein-lipid interplay. These explorations are key for elucidating cellular homeostasis and the pathological disruptions that lead to disease.

In conclusion, the unveiling of individual lipid transporter dynamics through advanced fluorescence microscopy heralds a new era in cellular biochemistry. This technological and conceptual advance provides a crucial lens to interrogate the heterogeneity and regulation of crucial transport proteins, broadening our understanding of lipid biology and opening avenues for targeted biomedical innovations that address mitochondrial health and related disorders.

Subject of Research: Cells
Article Title: A Single Vesicle Fluorescence Microscopy Platform to Quantify Phospholipid Scrambling
News Publication Date: 15-Jun-2026
Web References: https://doi.org/10.1038/s41594-026-01821-8
Image Credits: © Günther-Pomorski
Keywords: lipid transport, VDAC1, mitochondrial lipid supply, single vesicle microscopy, phospholipid scrambling, protein dimerization, membrane biology, fluorescence microscopy, lipid transporter heterogeneity, mitochondrial function, molecular simulation, cellular membranes

In the quest to unlock new frontiers in chemical synthesis, researchers are persistently searching for innovative methods that allow the formation and manipulation of molecular bonds in unprecedented ways. A remarkable breakthrough has emerged from the laboratory of Professor Yang Yang at the University of California, Santa Barbara, where his team has pioneered a novel class of biocatalytic reactions that blend the power of enzymatic catalysis with advances in photochemistry. This groundbreaking research, recently published in the prestigious journal Nature Catalysis, reveals a previously unknown mechanism for carbon-carbon bond formation via metal-carbene chemistry, fundamentally expanding the toolkit available to chemists for building complex molecules.

Transition metal carbene chemistry has been a vibrant area of study for decades, owing to the unique reactivity of metal-carbene intermediates—transient species in which a metal center is bound to a divalent carbon atom. These metal-carbenes act as powerful but fleeting intermediates, able to forge key carbon-carbon bonds essential for constructing the diverse frameworks found in pharmaceuticals, agrochemicals, and advanced materials. Despite their importance, the mechanistic landscape of metal-carbene chemistry remained relatively constrained, with well-established pathways that have been refined but seldom revolutionized—until now.

Professor Yang’s innovative approach combines two distinct catalytic cycles working in synergy: a light-driven photoredox cycle and an enzymatic metalloenzyme catalytic cycle. This integration ushers in a new paradigm where photochemically generated radical intermediates are directly coupled with enzymatically created iron-carbenoid intermediates. This union facilitates an intermolecular carbon-carbon bond-forming reaction that exploits radical intermediates in a controlled enzymatic environment—an achievement that not only challenges existing dogmas but also heralds unprecedented control over reaction selectivity and efficiency.

Central to this discovery is the use of directed evolution to engineer a metalloprotein catalyst capable of hosting iron ions within its active site. This finely tuned protein environment not only produces the iron-carbenoid intermediate but also exercises exquisite control over the highly reactive iron-radical intermediates generated during the photochemical step. The enzyme facilitates the crucial proton transfer step, a fundamental transformation in organic synthesis, with a precision that synthetic catalysts have struggled to match. Without this engineered metalloenzyme, the researchers believe this distinctive chemistry would have likely remained undisclosed.

The cooperation between photoredox catalysis and metalloenzyme activity effectively pushes the boundaries of transition metal carbene chemistry, offering a synthetic strategy with considerable generality. The dual catalytic system provides a versatile platform for carbon-carbon bond formation, accommodating a broad range of substrates and enabling the construction of molecules featuring multiple stereogenic centers. Such stereochemical complexity is vital for function in biologically active compounds, underscoring the potential impact on drug discovery and the design of agrochemical agents.

Photoredox catalysis has garnered significant attention in recent years for its ability to harness visible light energy to access radical intermediates under mild conditions. By integrating this with a metalloenzyme cycle, Yang’s team has pioneered a cooperative catalytic process that allows controlled radical coupling in a biological setting, effectively marrying the finesse of enzymatic catalysis with the versatility of photochemistry. This represents a new frontier in synthetic methodology, where light-powered biocatalysts can orchestrate complex chemical transformations with enhanced selectivity and sustainability.

The intricate mechanistic interplay revealed through this work demonstrates how radicals—often regarded as indiscriminate and challenging to control—can be tamed within an enzymatic pocket. The iron center in the metalloenzyme acts as a conductor, directing the radical pathway toward selective bond formation, while the protein scaffold stabilizes ephemeral intermediates. This fine balance of reactivity and control is unprecedented in the realm of metallocarbene chemistry and exemplifies the power of directed evolution in tailoring enzyme function for synthetic purposes.

Beyond method development, the researchers anticipate a wide spectrum of applications that could flow from this approach. The ability to generate complex, chiral molecules with high precision opens doors for the synthesis of fine chemicals and bioactive compounds that were previously difficult or impractical to obtain. Moreover, the modularity of this dual catalytic platform suggests that it could be expanded to include other metal centers and reaction types, fostering a versatile toolkit adaptable to diverse chemical challenges.

The collaborative nature of this research, involving experts from UCSB, the University of Pittsburgh, and Florida State University, highlights the interdisciplinary effort required to unravel such complex chemistry. Combining expertise in enzymology, photoredox catalysis, organometallic chemistry, and computational modeling was crucial in elucidating the mechanism and optimizing the catalytic system. This synergy underlines the importance of collaborative approaches in pushing the boundaries of contemporary chemical science.

Moving forward, the team plans to generalize this transformative methodology to broaden its applicability. By exploring additional substrates and refining the biocatalyst through further rounds of directed evolution, they aim to generate a diverse array of synthetically valuable molecules. This work not only deepens fundamental mechanistic understanding but also provides a roadmap for integrating photochemical activation with biocatalysis, opening avenues for green and sustainable synthesis.

In summary, the discovery of this new metal-carbene chemistry mechanism represents a significant leap in transition metal catalysis. It leverages the specificity and tunability of metalloenzymes engineered by directed evolution, combined with the power of photochemistry, to orchestrate complex carbon-carbon bond-forming reactions with unprecedented control. This advancement is poised to transform the synthesis of stereochemically rich molecules critical to pharmaceuticals and agrochemicals, catalyzing further innovation in both academic and industrial chemistry.

Subject of Research: Novel metal-carbene biocatalytic reactions enabling carbon-carbon bond formation through integrated photoredox and metalloenzyme catalysis.

Article Title: (Information not provided)

News Publication Date: (Information not provided)

Web References:

• Nature Catalysis Article
• Yang Yang UCSB Faculty Page

References: Research by Yang’s lab including Huanan Wang, Chongtao Li, Xiao-Wang Chen at UCSB; Peng Liu and Binh Khanh Mai at the University of Pittsburgh; Rachel Weiss and Bryan Kudisch at Florida State University.

Image Credits: (Information not provided)

Keywords

Physical sciences, Chemistry, Chemical reactions, Organic chemistry, Organometallic chemistry, Stereochemistry